ES2179261T3 - Vacuna a base de streptococcus equi. - Google Patents

Vacuna a base de streptococcus equi.

Info

Publication number
ES2179261T3
ES2179261T3 ES97200194T ES97200194T ES2179261T3 ES 2179261 T3 ES2179261 T3 ES 2179261T3 ES 97200194 T ES97200194 T ES 97200194T ES 97200194 T ES97200194 T ES 97200194T ES 2179261 T3 ES2179261 T3 ES 2179261T3
Authority
ES
Spain
Prior art keywords
streptococcus equi
based vaccine
vaccine
preparation
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97200194T
Other languages
English (en)
Inventor
Orla Mary Hartford
Timothy James Foster
Antonius Arnoldus Crist Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Original Assignee
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8223610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2179261(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin filed Critical College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Application granted granted Critical
Publication of ES2179261T3 publication Critical patent/ES2179261T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA CEPA VIVA ATENUADA DE LA BACTERIA STREPTOCOCCUS EQUI, UN PATOGENO QUE CAUSA ADIVAS EN CABALLOS. LA INVENCION TAMBIEN SE REFIERE A UNA VACUNA CONTRA ADIVAS, METODOS PARA LA PREPARACION DE DICHA VACUNA Y AL USO DE LA CEPA PARA LA PREPARACION DE DICHA VACUNA.
ES97200194T 1996-01-25 1997-01-24 Vacuna a base de streptococcus equi. Expired - Lifetime ES2179261T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96200171 1996-01-25

Publications (1)

Publication Number Publication Date
ES2179261T3 true ES2179261T3 (es) 2003-01-16

Family

ID=8223610

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97200194T Expired - Lifetime ES2179261T3 (es) 1996-01-25 1997-01-24 Vacuna a base de streptococcus equi.

Country Status (16)

Country Link
US (1) US5895654A (es)
EP (1) EP0786518B1 (es)
JP (1) JP3911058B2 (es)
AT (1) ATE219511T1 (es)
AU (1) AU703942B2 (es)
BR (1) BRPI9700768B8 (es)
CA (1) CA2195935C (es)
CZ (1) CZ289530B6 (es)
DE (1) DE69713408T2 (es)
DK (1) DK0786518T3 (es)
ES (1) ES2179261T3 (es)
NZ (1) NZ314091A (es)
PL (1) PL187163B1 (es)
PT (1) PT786518E (es)
RU (1) RU2194752C2 (es)
ZA (1) ZA97452B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682745B1 (en) 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2253839T3 (es) * 1997-12-03 2006-06-01 Neuralab, Ltd. Supresion de cambios relacionados con amiloide beta en la enfermedad de alzheimer.
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
DE60007668T2 (de) * 1999-01-26 2004-12-02 Akzo Nobel N.V. Verwendung lebender abgeschwächter Bakterien zur Herstellung eines submukosalen Impstoffes
US6541458B1 (en) 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
FR2796397B1 (fr) * 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
US6730065B1 (en) 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US20020082288A1 (en) * 1999-09-16 2002-06-27 Gerald Horn Ophthalmic formulations comprising an imidazoline
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
US8889112B2 (en) * 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PT2182983E (pt) * 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0801326D0 (en) 2008-01-24 2008-03-05 Animal Health Trust Vaccines
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
GB201209014D0 (en) * 2012-05-22 2012-07-04 Moredun Res Inst Vaccine
AU2014212274A1 (en) 2013-02-01 2015-08-13 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
AU2014212275B2 (en) 2013-02-01 2018-09-06 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
WO2015057777A1 (en) 2013-10-17 2015-04-23 Zoetis Llc Methods and compositions for treatment of s. equi infection
EP2949340A1 (en) * 2014-05-30 2015-12-02 IDT Biologika GmbH Vaccine composition against Streptococcus suis infection
GB2564481B (en) * 2017-07-14 2019-10-23 4D Pharma Leon S L U Process
WO2020087021A1 (en) 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110433A (en) * 1976-04-23 1978-08-29 Philips Roxane, Inc. Equine rhinopneumonitis virus
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4582798A (en) * 1984-11-23 1986-04-15 Miles Laboratories, Inc. Preparation and use of enzyme-detergent extracted Streptococcus equi vaccine
AR241545A1 (es) * 1985-07-12 1992-08-31 Cornell Res Foundation Inc Un metodo para preparar una cepa de s. equi avirulenta a.t.c.c. 53186 para equinos.
US4788059A (en) * 1985-07-15 1988-11-29 Coopers Animal Health, Inc. Equine strangles vaccine and the method of preparing and using the same
US5468485A (en) * 1987-06-04 1995-11-21 Washington University Avirulent microbes and uses therefor
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
JPH04501351A (ja) * 1987-10-07 1992-03-12 ワシントン ユニバーシティ 細胞の遺伝的集団において所望の組換え遺伝子を維持する方法
EP0626452B1 (en) * 1993-05-17 1999-08-11 Akzo Nobel N.V. Vaccine against Streptococcus suis infection
DE69417717T2 (de) * 1993-12-20 1999-10-07 Akzo Nobel N.V., Arnheim/Arnhem Impstoff zum Schutze von Pferden gegen Pferdeherpesvirus-Infektionen

Also Published As

Publication number Publication date
US5895654A (en) 1999-04-20
ZA97452B (en) 1997-08-15
CZ289530B6 (cs) 2002-02-13
EP0786518A1 (en) 1997-07-30
CZ21497A3 (cs) 1998-03-18
PL318095A1 (en) 1997-08-04
BRPI9700768B1 (pt) 2008-11-04
JPH09215492A (ja) 1997-08-19
AU703942B2 (en) 1999-04-01
ATE219511T1 (de) 2002-07-15
PL187163B1 (pl) 2004-05-31
DE69713408T2 (de) 2002-11-21
RU2194752C2 (ru) 2002-12-20
DK0786518T3 (da) 2002-09-16
EP0786518B1 (en) 2002-06-19
DE69713408D1 (de) 2002-07-25
PT786518E (pt) 2002-10-31
BRPI9700768B8 (pt) 2016-11-16
BR9700768A (pt) 1998-11-03
JP3911058B2 (ja) 2007-05-09
CA2195935C (en) 2006-06-27
NZ314091A (en) 1998-06-26
CA2195935A1 (en) 1997-07-26
AU1234697A (en) 1997-08-07

Similar Documents

Publication Publication Date Title
ES2179261T3 (es) Vacuna a base de streptococcus equi.
MY125202A (en) Vaccine
GB9713156D0 (en) Vaccines
FI914564A (fi) Foerbaettrade konjugerade oligosackaridvacciner.
ATE229978T1 (de) Helicobacter proteine und impstoffe
DE69327534D1 (de) Impfstoffe gegen diphtherietoxin
MY113428A (en) Hepatitis b vaccine
HK1080506A1 (en) Fusion proteins of mycobacterium tuberculosis
AP2000001886A0 (en) Group B streptococcus antigens.
IL118603A0 (en) Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
ATE246936T1 (de) Kombiniertes menningitis vakzine
GB9808327D0 (en) Antidiotypic compounds
PT807178E (pt) Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose
DE69533673D1 (de) Behandlung und prävention von helicobacter-infektionen
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
DE60136563D1 (de) Salmonella vakzine
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
FR2715304B1 (fr) Vaccin anti-allergique.
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
BR9707667A (pt) Complexos imunogênicos na forma de iscoms.
SE9602149D0 (sv) Conjugate vaccine against streptococcus pneumoniae
RU96116250A (ru) Штамм pestivirus, используемый для изготовления лапинизированной вирус вакцины против классической чумы свиней
UA32269A (uk) Спосіб лікування пневмоній у дітей